

Fax: 1.858.481.8694 Email: info@bpsbioscience.com

# **Data Sheet**

## PDE7A/CRE Reporter - HEK293 Cell Line Catalog #: 60413

## **Description**

Phosphodiesterases (PDEs) regulate the intracellular levels of cAMP and cGMP by hydrolyzing cAMP and cGMP to their inactive 5' monophosphates. These cyclic nucleotides play an important role as second messengers in diverse physiological functions. PDE7 is a cAMP-specific enzyme and two PDE7 genes (PDE7A and PDE7B) have been identified. PDE7A is widely expressed in various tissues including skeletal muscle, T lymphocytes, brain and pancreas. Inhibition of PDE7 activity by its inhibitors leads to elevated intracellular level of cAMP.

The regulation of intracellular level of cAMP by PDE7A in cells can be monitored by a specific reporter for the cAMP pathway, the CRE luciferase reporter. CRE luciferase reporter contains a luciferase gene that is under the control of the cAMP response element (CRE). Elevation of intracellular cAMP activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase.

The PDE7A/CRE Reporter-HEK293 line contains the firefly luciferase gene under the control of CRE as well as a constitutive expression construct for human PDE7A (phosphodiesterase 7A, accession number NM\_002603), both stably integrated into HEK293 cells. The luciferase expression level from the CRE reporter is used to monitor the activity of PDE7A in the cells. The cell line is validated for the induction of the expression of luciferase reporter by an inhibitor of PDE7A.

## Application

- Monitor human PDE7A activity.
- Screen for PDE7A inhibitors.

## **Format**

Each vial contains ~2 X 10<sup>6</sup> cells in 1 ml of 10% DMSO.



Fax: 1.858.481.8694
Email: info@bpsbioscience.com

## **Functional Validation and Assay Performance**

N-terminal FLAG-tagged human PDE7A is stably expressed in a human embryonic kidney (HEK293) cell line. PDE7A expression was confirmed by Western blotting.

PDE7A activity was monitored by CRE luciferase activity assay. Forskolin is commonly used to raise the intracellular level of cAMP in cell physiology studies. Forskolin resensitizes cell receptors by activating the enzyme adenylyl cyclase and increasing cAMP levels. When cells were activated by forskolin, the level of cAMP was upregulated in control HEK293 cells containing only CRE luciferase reporter (CRE Reporter-HEK293) inducing high expression of the CRE luciferase reporter. However, PDE7A/CRE Reporter-HEK293 cells showed reduction in the level of forskolin-induced cAMP, resulting in lowered expression of luciferase. Inhibition of PDE7A activity by BRL 50481, a PDE7A inhibitor, restored the cAMP level, resulting in higher luciferase activity (See figure 1., below).

# Assay performance: Induction of CRE reporter activity by PDE7A inhibitor in PDE7A /CRE Reporter – HEK293 cells

The following assays are designed for 96-well format. To perform the assay in different tissue culture formats, the cell number and reagent volumes should be scaled appropriately.

## Materials Required but Not Supplied

- BRL50481 (Enzo # BML-PD120): PDE7A inhibitor. Prepare 100 mM of stock solution in DMSO.
- Forskolin: prepare 10 mM of stock solution in DMSO.
- Assay medium: growth medium without Geneticin and Hygromycin
- 96-well tissue culture plate or 96-well tissue culture-treated white clearbottom assay plate (Corning # 3610)
- ONE-Step<sup>™</sup> luciferase assay system (BPS Bioscience, #60690) or other luciferase reagent for measuring firefly luciferase activity
- Luminometer
- Harvest cells from culture in Growth medium and seed cells at a density of ~30,000 cells per well in 40μl of assay medium in a white clear-bottom 96well microplate.
- Dilute PDE7A inhibitor (BRL50481) stock in assay medium. Add 10 μl of diluted inhibitor to wells. The final DMSO concentration in our assay is 0.1% (the final DMSO concentration may be up to 0.5%).



Fax: 1.858.481.8694
Email: info@bpsbioscience.com

Add 10 µl of assay medium containing the same concentration of DMSO to control wells without inhibitor.

Add 50  $\mu$ I of assay medium with 0.1% DMSO to cell-free control wells (for determining background luminescence).

Tap the plate gently to mix. Make sure that the cells distribute evenly in the wells.

- 3. Incubate at 37°C in a CO<sub>2</sub> incubator for ~ 16 hours.
- 4. The next day, cells should be  $\sim$  80% confluent. Dilute Forskolin in assay medium to 10  $\mu$ M and add 5.5  $\mu$ I of diluted Forskolin to stimulated wells. The final Forskoin concentration in the wells is 1  $\mu$ M.

Add 5.5 µl of assay medium with the same concentration of DMSO to the unstimulated control wells and cell-free control wells.

Tap the plate *very gently* to mix. Make sure that cells remain attached to the wells.

Set up each treatment in at least triplicate.

- 5. Incubate the plate at 37°C in a CO<sub>2</sub> incubator for 5-6 hours.
- 6. Perform luciferase assay using ONE-Step™ luciferase assay system: Add 50 µl of ONE-Step Luciferase reagent per well and rock at room temperature for ~15 minutes. Measure luminescence using a luminometer. If using other luciferase reagents from other vendors, follow the manufacturer's assay protocol.
- 7. Data Analysis: Subtract average background luminescence (cell-free control wells) from luminescence reading of all wells. The fold induction of CRE luciferase reporter expression = average background-subtracted luminescence of Forskolin-stimulated wells / average background-subtracted luminescence of unstimulated control wells



Fax: 1.858.481.8694
Email: info@bpsbioscience.com

Figure 1. PDE7A overexpression reduces the level of cAMP following forskolin stimulation in PDE7A /CRE-HEK293 cells. This effect is reversed by BRL 50481, a PDE7A inhibitor.

The data are shown as fold induction of CRE luciferase reporter activity. Fold induction was determined by comparing values against the mean value for control cells without forskolin treatment (fold induction =background-subtracted luminescence of Forskolin-stimulated wells / average background-subtracted luminescence of unstimulated control wells).





Figure 2. BRL50481 inhibition dose response curve in PDE7A /CRE Reporter cells.



Fax: 1.858.481.8694
Email: info@bpsbioscience.com

The result is shown as background-subtracted luminescence intensity. The inhibition of PDE7A in cells induces luminescence, so the inhibitory effects of BRL50481 on PDE7A activity is expressed as EC50. The EC50 of BRL50481 is  $\sim 8.26 \, \mu M$ .



## Mycoplasma testing

The cell line has been screened using the PCR-based Venor®GeM Mycoplasma Detection kit (Sigma-Aldrich) to confirm the absence of Mycoplasma species.

## Storage

Store cells in liquid nitrogen upon arrival.

## **Culture conditions**

Cells should be grown at  $37^{\circ}$ C with 5% CO<sub>2</sub> using MEM/EBSS (with L-glutamine) (Hyclone #SH30024.01) medium supplemented with 10% FBS (Life technologies #26140-079), 1% non-essential amino acids (Hyclone #SH30238.01), 1 mM Na pyruvate (Hyclone #SH30239.01), 1% Penicillin/Streptomycin (Hyclone SV30010.01), plus 400 µg/ml of Geneticin (Life technologies #11811031) and 50 µg/ml of Hygromycin B (Hyclone #SV30070.01). It may be necessary to adjust the percentage of CO<sub>2</sub> in the incubator depending on the NaHCO<sub>3</sub> level in the basal medium.

It is recommended to quickly thaw the frozen cells from liquid nitrogen in a 37°C water-bath, transfer to a tube containing 10 ml of growth medium **without** 

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone 1.858.829.3082 Fax 1.858.481.8694

Or you can Email us at: info@bpsbioscience.com



Fax: 1.858.481.8694
Email: info@bpsbioscience.com

Geneticin and Hygromycin, spin down cells, and resuspend cells in pre-warmed growth medium **without** Geneticin and Hygromycin. Transfer resuspended cells to a T25 flask and culture in a CO<sub>2</sub> incubator at 37°C overnight. The next day, replace the medium with fresh growth medium **without** Geneticin and Hygromycin, and continue growing culture in a CO<sub>2</sub> incubator at 37°C until the cells are ready to be split. At first passage, switch to growth medium containing Geneticin and Hygromycin. Cells should be split before they reach complete confluence.

To passage the cells, rinse cells with phosphate buffered saline (PBS), and detach cells from the culture vessel with 0.05% Trypsin/EDTA. Add complete growth medium and transfer to a tube, spin down the cells, then resuspend cells and seed appropriate aliquots of cell suspension into new culture vessels. Subcultivation ration: 1:10 to 1:20 weekly or twice a week.

## **Vector and sequence**

N-terminal FLAG-tagged human PDE7A (accession number NM\_002603) was cloned into pcDNA3.1 vector (Invitrogen).

Polylinker: CMV-HindIII-KpnI-BamHI-**PDE7A**-XhoI-XbaI-ApaI-----SV40-neomycin<sup>R</sup>

## hPDE7A sequence:

MDYKDDDÖKGITLIWCLALVLIKWITSKRRGAISYDSSDQTALYIRMLGDVRVRS RAGFESERRGSHPYIDFRIFHSQSEIEVSVSARNIRRLLSFQRYLRSSRFFRGTA VSNSLNILDDDYNGQAKCMLEKVGNWNFDIFLFDRLTNGNSLVSLTFHLFSLHG LIEYFHLDMMKLRRFLVMIQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLAN SVTPWDILLSLIAAATHDLDHPGVNQPFLIKTNHYLATLYKNTSVLENHHWRSAV GLLRESGLFSHLPLESRQQMETQIGALILATDISRQNEYLSLFRSHLDRGDLCLE DTRHRHLVLQMALKCADICNPCRTWELSKQWSEKVTEEFFHQGDIEKKYHLGV SPLCDRHTESIANIQIGFMTYLVEPLFTEWARFSNTRLSQTMLGHVGLNKASWK GLQREQSSSEDTDAAFELNSQLLPQENRLS



Fax: 1.858.829.3082
Fax: 1.858.481.8694
Email: info@bpsbioscience.com

## References

- 1. Malik, R. *et al.* (2008) Cloning, stable expression of human phosphodiesterase 7A and development of an assay for screening of PDE7 selective inhibitors. *Appl. Microbiol. Biotechnol.* **77 (5):** 1167-1173
- 2. Fan Chung, K. (2006) Phosphodiesterase inhibitors in airways disease. *Eur. J. Pharmacol.* **533(1-3):**110-117

## **License Disclosure**

Visit <u>bpsbioscience.com/license</u> for the label license and other key information about this product.

## **Related Products**

. tolatoa i roadoto		
Product Name	Catalog #	<u>Size</u>
CRE Reporter-HEK293 cell line	60613	2 vials
PDE7A-HEK293 Cell line	60407	2 vials
PDE7B-HEK293 Cell line	60412	2 vials
Rat PDE7A-HEK293 Cell line	60408	2 vials
CRE/CREB Kit (cAMP/PKA)	60611	500 rxns.
PDE4D Cell-Based Activity Assay Kit	60505	500 rxns.
PDE7A Enzyme (Human)	60070	10 μg
PDE7B Enzyme (Human)	60071	10 μg
PDE7A Enzyme (Rat)	60074	10 μg
PDE7B Enzyme (Rat)	60075	10 μg